Daniel Knecht, MD, MBA

Vice President & Chief Clinical Innovation Officer, CVS Caremark
Daniel Knecht, MD

Daniel Knecht, MD is a board-certified internist currently serving as Vice President and Chief Clinical Innovation Officer at CVS Caremark. In this role, he collaborates with clients as well as the product team to identify unmet needs in the marketplace and accelerate innovation to improve health outcomes and better manage costs. Prior to this role, Dr. Knecht served as VP of Clinical Product where he drove clinical product development across all major CVS Health business lines to develop and execute clinical strategies that address unmet health needs. Since joining the company in 2016, Dr. Knecht has led a series of enterprise-wide strategic initiatives including the company’s efforts to combat opioid misuse and addiction. As part of the combined organization, his team focused on leveraging data analytics and enterprise assets to provide actionable insights for patients and providers that increase value of care.

Dr. Knecht graduated with honors from Dartmouth College and received a joint MD, MBA from Weill Cornell Medical College and Johnson Graduate School of Management where he was a recipient of the Lee Family Scholarship. He is a Fulbright Scholar in medical sciences and has performed research that explored health care deficiencies in the Negev region of Israel. Dr. Knecht is also an associate clinical professional at Mount Sinai West in New York City where he still sees patients.

Drug Pipeline
Getting personal with mRNA vaccines for cancer More
Briefing
Care Management
Drive sustainable member behavior change for better health outcomes and cost savings More
Briefing
A worker tends to his garden.
Health Equity
Supporting Member Health in the Face of the Climate Crisis More
Briefing
Care Management
New obesity medications are here highlighting the need for managing access and cost. More
Briefing
Drug Pipeline
The different types of gene therapy and how they work More
Briefing
Specialty
The Top Challenges Facing Gene Therapy Today More
Briefing
Cost Management
New Dry Powder Inhalation Therapies for PAH in Pipeline More
Briefing